Introduction {#s1}
============

A fundamental question in chromosome biology is how cells differentiate between DNA double-strand breaks (DSBs) and telomeres, the natural ends of chromosomes. A failure to distinguish between these structures has severe consequences for genome integrity. For example, the engagement of the non-homologous end-joining pathway at telomeres can lead to breakage-fusion-bridge cycles that wreak havoc on the genome. Similarly, the activity of telomerase at DSBs can generate new telomeres at the cost of the genetic information distal to the break. Telomere addition has been observed in a variety of species ([@bib31]; [@bib3]; [@bib16]) and has been linked to human disorders involving terminal deletions of chromosome 16 ([@bib66]) and 22 ([@bib67]). While DSBs and telomeres reflect extreme positions on the spectrum, a continuum of DNA ends exists between them, including critically short telomeres and DSBs occurring in telomeric-like sequence. All these require a decision: should the end be repaired or should it be elongated by telomerase?

The budding yeast *Saccharomyces cerevisiae,* whose telomeres consist of 300 ± 75 bp of heterogeneous (TG~1-3~)~n~ repeats, has been a key model to study mechanisms of genomic stability ([@bib69]). The telomere repeats organize a nucleoprotein structure minimally composed of the double-stranded (ds) DNA binding protein Rap1, its interacting factors Rif1 and Rif2, and the telomere-specific single-stranded (ss) DNA-binding Cdc13-Stn1-Ten1 (CST) complex, which caps the chromosome ends ([@bib11]). These telomere-bound proteins prevent activation of DNA damage signaling pathways and the ability of the DSB repair machinery to use telomeric ends as substrates. This so-called capping function is a universal property of eukaryotic telomeres; while different in composition, a set of human proteins collectively known as shelterin accomplishes a similar function in human cells ([@bib49]).

Telomerase-mediated extension does not occur at every telomere in every cell cycle, but the probability of telomere extension steadily increases as telomere length decreases ([@bib61]). Telomerase also acts more processively at telomeres less than 125 bp in length, resulting in more extensive elongation of critically short telomeres ([@bib5]). The preferential extension of short telomeres can be rationalized since short telomeres are most in danger of becoming dysfunctional. Thus, while telomerase must be tightly inhibited at DSBs, its activity must also be suppressed at telomeres that are sufficiently long. A number of proteins have been implicated in this process, including Rif1, Rif2, and the Tel1 (ATM) kinase (reviewed in [@bib65]). In addition, the telomerase inhibitor Pif1, which is a helicase that unwinds RNA-DNA hybrids in vitro and removes telomerase from telomeric DNA ([@bib4]), has recently been shown to act preferentially at long telomeres ([@bib51]).

Remarkably, Pif1 is also required to inhibit telomerase at DSBs. Pif1 has both mitochondrial and nuclear isoforms encoded from separate translational start sites; mutation of the second start site in the *pif1-m2* mutant abolishes the nuclear isoform, resulting in telomere elongation ([@bib56]) and a 240-fold increase in telomere addition at DSBs ([@bib46]). The Mec1 (ATR)-dependent phosphorylation of Cdc13 also guards against the inappropriate recruitment of the CST complex to DSB sites ([@bib70]).

One striking feature of Pif1 is that it is able to distinguish between DSBs and telomeres, as a *pif1-4A* mutant affects telomere addition frequency at DSBs but without influencing native telomere length ([@bib39]). This observation makes Pif1 an attractive candidate for a protein that controls the distinction between DSBs and short telomeres. We noted in our previous work that Pif1 suppresses telomere addition at HO-induced DSBs containing 18 bp of (TG~1-3~)~n~ telomeric repeats (referred to as TG~18~) but has no impact on the telomerase-dependent elongation of DNA ends containing a TG~82~ sequence ([@bib70]). This observation suggests that the TG~82~ substrate behaves as a critically short telomere and that cells elongate it in a manner that is uninhibited by Pif1. Thus, this system appears to recapitulate the end-fate decisions undertaken at DSBs versus critically short telomeres.

Results {#s2}
=======

Identification of a Pif1-insensitivity threshold at DNA ends {#s2-1}
------------------------------------------------------------

To characterize the dividing line between a DSB and a short telomere, we used a genetic system in which galactose-inducible HO endonuclease can be expressed to create a single DSB at the *ADH4* locus on Chr VII-L ([@bib12]; [@bib22]). By placing different lengths of telomeric (TG~1-3~)~n~ sequence immediately adjacent to the HO cut site, one can study the fate of DNA ends using two readouts: a genetic assay for telomere addition based on the loss of the distal *LYS2* marker, and by Southern blotting to monitor the length of the DNA end ([Figure 1a,b](#fig1){ref-type="fig"}). The HO cut site in this system contributes one thymine nucleotide to the inserted telomeric seed, accounting for a one base pair discrepancy from prior reports. As previous work indicated that Pif1 is active at TG~18~, but not TG~82~ ([@bib70]), we first constructed strains containing 34, 45, 56, and 67 bp of telomeric repeats in both wild-type and *pif1-m2* cells (see [Supplementary file 1A](#supp1){ref-type="supplementary-material"} for all TG repeat sequences). We observed similar rates of telomere addition at all DNA ends in both backgrounds, indicating that 34 bp of telomeric repeats are sufficient to render a DNA end insensitive to Pif1 ([Figure 1c](#fig1){ref-type="fig"}; source data are available in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). To account for variations in HO cutting efficiency and the propensity to recruit telomerase at each DNA end, we also normalized telomere addition frequency to *pif1-m2* cells to provide a clear readout of Pif1 activity ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}; source data are available in [Figure 1---figure supplement 1---source data 1](#fig1s1sdata1){ref-type="supplementary-material"}). Analysis of DNA ends by Southern blot also revealed robust telomere addition at the TG~34~ substrate in *PIF1* cells, mirroring the results of the genetic assay ([Figure 1d](#fig1){ref-type="fig"}).

![Characterization of Pif1 activity at DNA ends reveals a DSB-telomere transition.\
(**a**) Schematic of a system to study the fate of DNA ends. Telomeric repeats are placed adjacent to an HO cut site (HOcs) at the *ADH4* locus on Chr VII. Telomere addition can be measured using a genetic assay based on the loss of the distal *LYS2* gene as measured by resistance to α-aminoadipic acid. Southern blotting with a probe complementary to *URA3* (black bar) allows for visualization of DNA end stability. (**b**) Sequence of the TG~18~ substrate and the overhang produced by the HO endonuclease. The C-rich strand runs 5' to 3' toward the centromere and is resected following DSB induction to expose a 3' G-rich overhang. (**c**) Telomere addition frequency at DNA ends containing 18--82 bp of TG sequence. Data represent the mean ± s.d. from a minimum of n = 3 independent experiments. See [Supplementary file 1a](#supp1){ref-type="supplementary-material"} for the sequences of all DNA ends and source data are found in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. (**d**) Southern blot of DNA ends containing TG~18~ and TG~34~ ends in wild-type and *pif1-m2* cells following HO induction. A *URA3* probe was used to label the *ura3-52* internal control (INT) and the *URA3* gene adjacent to the TG~n~-HO insert (PRE) which is cleaved by HO endonuclease (CUT). Newly added telomeres are visualized as a heterogeneous smear above the CUT band. (**e**) Telomere addition frequency normalized to *pif1-m2* cells at DNA ends containing 18--38 bp of TG sequence. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}. (**f**) Summary of telomere addition frequency normalized to *pif1-m2* across the spectrum of TG repeat substrates. Source data are found in [Figure 1---source data 3](#fig1sdata3){ref-type="supplementary-material"}.\
10.7554/eLife.23783.004Figure 1---source data 1.Raw data for telomere addition assays shown in [Figure 1c](#fig1){ref-type="fig"}.\
10.7554/eLife.23783.005Figure 1---source data 2.Raw data for telomere addition assays shown in [Figure 1e](#fig1){ref-type="fig"}.\
10.7554/eLife.23783.006Figure 1---source data 3.Raw data telomere addition assays shown in [Figure 1f](#fig1){ref-type="fig"}.](elife-23783-fig1){#fig1}

The standard genetic telomere addition assay includes a nocodazole arrest before DSB induction, as telomerase is active in S/G2 phase ([@bib12]). However, asynchronously dividing cells also exhibited a similar phenotype at the TG~18~ and TG~34~ ends ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}; source data are available in [Figure 1---figure supplement 1---source data 2](#fig1s1sdata2){ref-type="supplementary-material"}). To exclusively study telomere addition by telomerase and not through homologous recombination, telomere addition strains also harbored a *rad52Δ* mutation. The addition of *RAD52* in this assay reduced telomere addition at the TG~18~ end in *pif1-m2* cells but had no impact on the behavior of Pif1 at the TG~34~ substrate ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}).

To further refine the Pif1-insensitivity threshold, we added 4 bp increments of TG repeat sequence to the centromeric side of the TG~18~ substrate yielding strains with 22, 26, 30, 34, and 38 bp of telomeric repeats. Importantly, with the exception of length, these strains contained the same DNA sequence and shared a common distal end. Analysis of telomere addition revealed that Pif1 is active at DNA ends up to TG~26~, while the frequency of telomere addition increased at the TG~30~ end and beyond ([Figure 1e](#fig1){ref-type="fig"}; source data are available in [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). As telomeric repeats are heterogeneous in nature, we next determined if this phenotype is dependent on the particular DNA sequence. We selected three different sequences from *S. cerevisiae* telomeric DNA and constructed strains with DNA ends containing either 26 or 36 bp of each sequence. Consistent with our initial observations, telomere addition was inhibited by Pif1 at all TG~26~ ends, while the corresponding TG~36~ ends resulted in telomere addition in the presence of Pif1 ([Figure 1---figure supplement 1c,d](#fig1s1){ref-type="fig"}; source data for panel c are available in [Figure 1---figure supplement 1---source data 3](#fig1s1sdata3){ref-type="supplementary-material"}).

Visualization of the combined genetic assay results across different lengths of TG-repeat substrates reveals a striking transition with regard to Pif1 function ([Figure 1f](#fig1){ref-type="fig"}; source data are available in [Figure 1---source data 3](#fig1sdata3){ref-type="supplementary-material"}). By using Pif1-insensitivity as an operational definition of a short telomere, we propose that the 26 to 34 bp window of telomeric sequence is the dividing line between what the cell interprets to be a DSB and what is considered to be a critically short telomere. These data suggest that DNA ends containing 34 bp or more of telomeric DNA are allowed to elongate in a manner unimpeded by Pif1 and we herein refer to this phenomenon as the DSB-telomere transition.

A DSB-telomere transition also exists at chromosome ends {#s2-2}
--------------------------------------------------------

To validate the threshold that defines the DSB-telomere transition, we set up a system based on the STEX (Single Telomere EXtension) assay to monitor telomerase-mediated extension events at chromosome ends at nucleotide resolution after a single cell cycle ([@bib61]). In the STEX assay, a clonal population of telomerase-negative cells is mated to a strain expressing telomerase. Telomeres that had shortened in the telomerase-negative cells can then be re-extended in the zygote. DNA is isolated from the zygotes and telomere elongation can be detected by amplifying, cloning and sequencing telomeres originating from the telomerase-negative strain. Since yeast telomerase adds imperfect 5′-(TG)~0-6~TGGGTGTG(G)~0-1~-3' repeats ([@bib19]), telomere elongation can be detected after sequence alignment of the telomeres because newly added sequences do not align with the non-elongated telomeres. We call these newly added sequences 'sequence divergence events' because they diverge from the original sequences. We introduced two major modifications to the STEX assay: (1) we use a strain where the expression of *EST1*, encoding a subunit of telomerase ([@bib36]), is under the control of a galactose-inducible promoter, allowing us to avoid the challengingly high mating efficiency needed in the classical STEX assay; (2) we make use of a *tlc1* template mutant (*tlc1-tm*) that introduces 5′-\[(TG)~0--4~TGG\]~n~ATTTGG-3' telomeric repeats ([@bib5]), enabling us to distinguish sequence divergence events that are telomerase-dependent (i.e. the divergent sequence is mutant) from those that are telomerase-independent (i.e. the divergent sequence is wild type). This modification was found to be important since a fraction of sequence divergence events can occur due to homologous recombination, as well as from errors introduced during amplification, cloning and sequencing of the telomeres ([@bib8]). Importantly, our iSTEX (for inducible STEX) data are similar to previously published STEX data ([@bib61]; [@bib2]; [@bib30]) in terms of the frequency and extent of telomere elongation events, and use of the *tlc1-tm* mutant does not significantly affect the repeat addition processivity of telomerase ([@bib5]).

In this revised assay, we transform a PCR fragment containing the *tlc1-tm* allele into a strain with *EST1* under the control of a galactose-inducible promoter ([Figure 2a](#fig2){ref-type="fig"}). From the moment we transform strains with the *tlc1-tm* PCR fragment, we keep the cells in media containing glucose, which shuts off *EST1* expression and causes the telomeres to shorten. We then arrest successfully transformed cells in late G1 phase and release them in the presence of galactose to reactivate telomerase, allowing the addition of mutant sequences to the chromosome ends. We monitor the arrest/release efficiency by flow cytometry ([Figure 2b](#fig2){ref-type="fig"}), extract genomic DNA from released cells that have completed DNA replication, amplify telomeres by PCR, and then clone and sequence telomeres.

![Characterization of the DSB-telomere transition at chromosome ends.\
(**a**) Methodology of the iSTEX assay; see text for details. (**b**) Arrest and release efficiency monitored by flow cytometry. (**c**) Telomere V-R was amplified, cloned and sequenced after 2 hr of *tlc1-tm* telomerase induction. Each bar represents an individual telomere. The black portion of each bar represents the undivergent sequence, the red portion shows the mutant divergent sequence and the grey portion indicates the wild-type divergent sequence. Telomeres are sorted based on the length of the undiverged sequence (black portion). The horizontal red line indicates the threshold below which telomerase-mediated telomere extension becomes very inefficient. Statistical analysis was done using a Fisher's exact test and for this analysis, telomeres containing only wild-type divergence were excluded. Source data are found in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. (**d**) As in panel (**c**) except in a *pif1-m2* background. Statistical analysis comparing extension of telomeres below 44 bp in length in wild type and *pif1-m2* was done using a Fisher's exact test. Source data are found in [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.23783.012Figure 2---source data 1.Raw data for iSTEX shown in [Figure 2c](#fig2){ref-type="fig"}.\
10.7554/eLife.23783.013Figure 2---source data 2.Raw data for iSTEX shown in [Figure 2d](#fig2){ref-type="fig"}.](elife-23783-fig2){#fig2}

We monitor telomere sequence addition at an engineered V-R telomere, which contains an *ADE2* marker placed adjacent to the telomere repeats ([@bib59]), and at the natural VI-R telomere. In agreement with previous reports ([@bib61]), there is a strong preference to elongate short telomeres \[([Figure 2c](#fig2){ref-type="fig"}; source data are available in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}) and ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}; source data are available in [Figure 2---figure supplement 1---source data 1](#fig2s1sdata1){ref-type="supplementary-material"})\] and the frequency of telomerase-independent sequence divergence events is similar to previous reports where telomerase is knocked out ([@bib61]; [@bib6]; [@bib8]). These data indicate that the presence of telomerase does not influence these events. Strikingly, at both the V-R and VI-R telomeres, the frequency of telomere extension drops dramatically at extremely short telomeres ([Figure 2c](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). At the V-R telomere, only two out of 32 telomeres (6.3%) shorter than 44 bp were extended by telomerase, while 65 out of 136 telomeres (47.8%) between 44 bp and 86 bp long were extended. Similarly, at the VI-R telomere, two of the 13 telomeres below 38 bp (15.4%) were extended, while 51 out of 115 telomeres (44.3%) between 38 bp and 74 bp long were extended. Thus, while telomerase preferentially elongates short telomeres, those below \~40 bp are inefficiently extended. These data suggest that the DSB-telomere transition identified at HO-induced breaks also exists at native chromosome ends.

To determine whether Pif1 is also important for the DSB-telomere transition at chromosome ends, the iSTEX assays were repeated in a *pif1-m2* background \[([Figure 2d](#fig2){ref-type="fig"}; source data are available in [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}) and ([Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}; source data are available in [Figure 2---figure supplement 1---source data 2](#fig2s1sdata2){ref-type="supplementary-material"})\]. At both the V-R and VI-R telomeres, the percentage of elongated telomeres below the DSB-telomere transition length determined in *PIF1* cells increased in the *pif1-m2* background (although statistical significance was not reached for the VI-R telomere due to difficulties in obtaining enough short telomeres for analysis). Thus, at both DSBs and chromosome ends, Pif1 is needed to set the DSB-telomere transition.

Pif1 is not inhibited by DNA damage kinases {#s2-3}
-------------------------------------------

One attractive mechanism for the observed DSB-telomere transition is that Pif1 might be inactivated at DNA ends containing telomeric repeats 34 bp in length or longer. Prime candidates for this regulation include the central DNA damage kinases including Mec1 (ATR), Tel1 (ATM), and Rad53 (CHK2). Previous work has identified that Tel1 promotes telomerase-mediated extension of a TG~82~ end ([@bib17]), and targets short telomeres for elongation ([@bib55]; [@bib25]; [@bib2]). As these results raised the possibility that Tel1 antagonizes Pif1, we deleted *TEL1* in wild-type and *pif1-m2* backgrounds and followed the fate of the TG~82~ DNA end by Southern blotting. Although telomere addition was reduced in *tel1Δ* cells, we observed a similar reduction in *tel1Δ pif1-m2* cells, indicating that *TEL1* and *PIF1* function in separate pathways ([Figure 3a,b](#fig3){ref-type="fig"}; source data for panel b are available in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Consistent with this observation, the loss of *TEL1* did not affect the DSB-telomere transition at the TG~18~ and TG~34~ DNA ends ([Figure 3c](#fig3){ref-type="fig"}; source data are available in [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Loss of *MEC1* and *RAD53* also failed to inhibit telomerase in a Pif1-specific manner at the TG~82~ end ([Figure 3---figure supplement 1a--d](#fig3s1){ref-type="fig"}; source data are available in [Figure 3---figure supplement 1---source data 1](#fig3s1sdata1){ref-type="supplementary-material"}, [2](#fig3s1sdata2){ref-type="supplementary-material"}). Pif1 contains five consensus S/T-Q Mec1 and Tel1 phosphorylation sites; however, their mutation in the *pif1-5AQ* allele (S148A/S180A/T206A/S707A/T811A) also did not decrease telomere addition at the TG~34~ end ([Figure 3d](#fig3){ref-type="fig"}; source data are available in [Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}).

![Pif1 is not inactivated by Tel1 at short telomeres.\
(**a, b**) Southern blot of the TG~82~ DNA end following HO-induction in wild-type (WT) and *pif1-m2* cells without or with a *TEL1* deletion. An *ADE2* probe was used to label the *ade2Δ1* internal control (INT) and the *ADE2* gene adjacent to the TG~n~-HO insert (PRE) which is cleaved by HO endonuclease (CUT). Quantification of the newly added telomere signal (**b**) calculated by subtracting the background signal present prior to HO-induction and by normalizing to the INT control. Data represent the mean ± s.d. from n = 2 independent experiments. Source data are found in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}. (**c**) Telomere addition frequency at the TG~18~ and TG~34~ DNA ends in *tel1Δ* mutants. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}. (**d**) Telomere addition frequency at the TG~34~ DNA end in *pif1-m2* cells (-) and cells expressing a wild-type (WT) or *pif1-5AQ* (S148A, S180A, T206A, S707A, T811A) nuclear-specific *pif1-m1* allele. Data represent the mean ± s.d. from n = 3 independent experiments. The functionality of the *pif1-m1* alleles was assessed by rescue of the telomere elongation associated with *pif1-m2* ([Figure 3---figure supplement 1e](#fig3s1){ref-type="fig"}). Source data are found in [Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}.\
10.7554/eLife.23783.018Figure 3---source data 1.Raw data for telomere addition assays shown in [Figure 3b](#fig3){ref-type="fig"}.\
10.7554/eLife.23783.019Figure 3---source data 2.Raw data for telomere addition assays shown in [Figure 3c](#fig3){ref-type="fig"}.\
10.7554/eLife.23783.020Figure 3---source data 3.Raw data for telomere addition assays shown in [Figure 3d](#fig3){ref-type="fig"}.](elife-23783-fig3){#fig3}

As Pif1 might be regulated through unanticipated post-translational modifications or protein-protein interactions, we performed a *PIF1* PCR mutagenesis screen to identify gain-of-function mutations that inhibit telomere addition at the TG~82~ end but we were unable to recover any mutants. Together, these data suggest that Pif1 is not directly inactivated at the TG~34~ and TG~82~ DNA ends, so we next considered alternative explanations for the observed DSB-telomere transition.

Artificial telomerase recruitment does not outcompete Pif1 {#s2-4}
----------------------------------------------------------

A simple explanation for the DSB-telomere transition is that longer telomeric repeats might have an increased ability to recruit telomerase. This model predicts that artificially increasing telomerase recruitment to the TG~18~ end might be sufficient to overcome Pif1 inhibition. Since the primary mechanism of telomerase recruitment involves an interaction between the DNA-binding protein Cdc13 and the Est1 telomerase subunit ([@bib47]; [@bib50]), we expressed Cdc13-Est1 and Cdc13-Est2 fusion proteins ([@bib15]) to test this possibility. In agreement with previous work, expression of both fusions resulted in greatly elongated telomeres ([@bib15]) ([Figure 4a](#fig4){ref-type="fig"}); however, they did not increase telomere addition at the TG~18~ DNA end in the presence of Pif1 ([Figure 4b](#fig4){ref-type="fig"}; source data are available in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). To test whether the Cdc13-Est1 fusion protein is able to bind and extend the TG~18~ substrate, we repeated the genetic telomere healing assay in *est1Δ* cells expressing a Cdc13-Est1 fusion containing the *est1-60* mutation (K444E) that disrupts the interaction of Est1 with endogenous Cdc13 ([@bib50]). Telomerase extension in these *est1Δ* cells must therefore arise from the ectopic construct. We observed that Cdc13-Est1^K444E^ can extend the TG~18~ end only in the absence of *PIF1* ([Figure 4b](#fig4){ref-type="fig"}). Together, these data indicate that Pif1 is able to effectively suppress telomere addition even in the presence of enhanced telomerase recruitment, suggesting that increased telomerase recruitment to the TG~34~ end is unlikely to underpin the observed DSB-telomere transition.

![The DSB-telomere transition recapitulates the differential regulation of Pif1.\
(**a**) Southern blot for telomere length in TG~18~-HO wild-type (WT) and *pif1-m2* cells harbouring an empty plasmid (-) or expressing plasmid-based Cdc13-Est1 or Cdc13-Est2 fusions. Cells were passaged for approximately 75 generations before genomic DNA extraction. A Y' TG probe was used to label telomeric sequences. (**b**) Telomere addition frequency of the cells described in panel (**a**) and *est1Δ* strains expressing a *cdc13-est1-60* (K444E) fusion. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}. (**c**) Telomere addition frequency at the TG~18~ and TG~34~ DNA ends in *pif1-m2* cells (-) and cells expressing a wild-type (WT), *pif1-4A* (T763A/S765A/S766A/S769A), or *pif1-4D* (T763A/S765A/S766A/S769A) nuclear-specific *pif1-m1* allele. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}. (**d**) Southern blot for telomere length in *PIF1* (WT) and *pif1-m2* cells combined with or without the *est2-up34* mutation. Cells were passaged for approximately 75 generations before genomic DNA extraction and a Y' TG probe was used to label telomere sequences. (**e**) Telomere addition frequency at the TG~18~ and TG~34~ DNA ends in *PIF1* and *pif1-m2* cells with or without the *est2-up34* mutation. Data represent the mean ± s.d. from n = 3 independent experiments. The *EST2* data are the same as the WT data shown in [Figure 3c](#fig3){ref-type="fig"}. Source data are found in [Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}.\
10.7554/eLife.23783.024Figure 4---source data 1.Raw data for telomere addition assays shown in [Figure 4b](#fig4){ref-type="fig"}.\
10.7554/eLife.23783.025Figure 4---source data 2.Raw data for telomere addition assays shown in [Figure 4c](#fig4){ref-type="fig"}.\
10.7554/eLife.23783.026Figure 4---source data 3.Raw data for telomere addition assays shown in [Figure 4e](#fig4){ref-type="fig"}.](elife-23783-fig4){#fig4}

The DSB-telomere transition recapitulates the differential regulation of Pif1 {#s2-5}
-----------------------------------------------------------------------------

Pif1 may only be activated at DNA ends with short tracts of telomeric sequence. Consistent with this model, Pif1 is reported to be phosphorylated after DNA damage in a Mec1-Rad53-Dun1-dependent manner and further characterization of this activity led to the identification of the *pif1-4A* mutant (T763A/S765A/S766A/S769A) that is unable to inhibit telomere addition at DSBs ([@bib39]). Importantly, mimicking phosphorylation with the *pif1-4D* allele can restore Pif1 activity ([@bib39]). We first confirmed the function of these mutants at the TG~18~ DNA end by integrating variants of the nuclear-specific *pif1-m1* allele at the *AUR1* locus in *pif1-m2* cells ([Figure 4c](#fig4){ref-type="fig"}; source data are available in [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). As expected, introducing the *pif1-m1* allele rescued the telomere lengthening phenotype of the *pif1-m2* allele ([Figure 3---figure supplement 1e](#fig3s1){ref-type="fig"}). If Pif1 phosphorylation only occurs at DNA ends with short lengths of telomeric repeats, such as TG~18~, then mimicking phosphorylation may be sufficient to inhibit telomere addition at DNA ends with longer telomeric repeats. Contrary to this prediction, the *pif1-4D* mutant did not restore Pif1 activity at the TG~34~ DNA end ([Figure 4c](#fig4){ref-type="fig"}), indicating that phosphorylation of these sites is not sufficient to regulate the DSB-telomere transition.

Several lines of evidence indicate that Pif1 functions differently at DSBs and telomeres. First, the *pif1-4A* mutation affects the frequency of telomere addition at DSBs, but does not affect native telomere length ([@bib39]). The inability of the *pif1-4D* allele to inhibit telomerase at TG~34~ therefore provides indirect evidence that the cell interprets this DNA end as a short telomere. A second mutation that affects Pif1 activity has also been identified: the *est2-up34* mutation, which affects the finger domain of the telomerase reverse transcriptase subunit ([@bib14]). Interestingly, the *est2-up34* mutant results in over-elongated telomeres in wild-type but not *pif1-m2* cells, indicating that the *est2-up34* allele can at least partially bypass Pif1 inhibition ([@bib14]). To test if this holds true at DSBs, we generated the *est2-up34* mutation in strains with a TG~18~ DNA end. Although we observed increased telomere length in *PIF1 est2-up34* cells ([Figure 4d](#fig4){ref-type="fig"}), telomere addition was not increased ([Figure 4e](#fig4){ref-type="fig"}; source data are available in [Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}), indicating that the *est2-up34* mutation can bypass Pif1 function at telomeres but not at DSBs. Together these data support the idea that Pif1 possesses distinct functions at DSBs and telomeres and that these differences are recapitulated in the TG~18~ and TG~34~ DNA ends on either side of the DSB-telomere transition.

Investigating the molecular trigger of the DSB-telomere transition {#s2-6}
------------------------------------------------------------------

Since our attempts thus far failed to identify a modification of Pif1 that would explain the DSB-telomere transition, we next focused on whether a property of the DNA end facilitates or blocks Pif1 activity. Attractive candidates included the MRX and Ku complexes, which are rapidly recruited to DNA ends and function in both DSB repair and telomere maintenance ([@bib11]). The loss of either complex, however, did not affect either side of the DSB-telomere transition ([Figure 5a](#fig5){ref-type="fig"}; source data are available in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}).

![The DSB-telomere transition does not require Rap1.\
(**a**) Telomere addition frequency at the TG~18~ and TG~34~ DNA ends in *mre11Δ* and *yku70Δ* mutants. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}. (**b**) Telomere addition frequency normalized to *pif1-m2* cells at DNA ends containing 26 bp or 36 bp of either (TGTGG)~n~ or (TG)~n~ repeats. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}. (**c**) Telomere addition frequency at the TG~18~ and TG~34~ DNA ends in *rif1Δ, rif2Δ*, and *rif1Δ rif2Δ* double mutants. Data represent the mean ± s.d. from n = 3 independent experiments. The WT data in panels (**a**) and (**c**) are the same as that shown in [Figure 3c](#fig3){ref-type="fig"}. Source data are found in [Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}.\
10.7554/eLife.23783.028Figure 5---source data 1.Raw data for telomere addition assays shown in [Figure 5a](#fig5){ref-type="fig"}.\
10.7554/eLife.23783.029Figure 5---source data 2.Raw data for telomere addition assays shown in [Figure 5b](#fig5){ref-type="fig"}.\
10.7554/eLife.23783.030Figure 5---source data 3.Raw data for telomere addition assays shown in [Figure 5c](#fig5){ref-type="fig"}.](elife-23783-fig5){#fig5}

Budding yeast telomeres are bound by two specialized proteins, Rap1 and Cdc13, and the binary nature of the DSB-telomere transition suggests that the discrete binding of either protein may trigger insensitivity to Pif1. As Cdc13 binds ssDNA at the distal end of the telomere ([@bib35]; [@bib47]), an attractive prediction is that Rap1 bound to double-stranded telomeric DNA of longer TG repeats might inhibit Pif1. This model nicely correlates with the observed length of the DSB-telomere transition, as Cdc13 and Rap1 bind DNA sequences of 11 bp ([@bib28]) and 18 bp, respectively ([@bib21]; [@bib54]). Rap1 has also been previously shown to stimulate telomere addition ([@bib24]; [@bib37]; [@bib53]).

Rap1 is an essential protein that binds the consensus DNA sequence of 5′-ACA[CCC]{.ul}ATACACC-3' containing an invariable CCC core ([@bib64]; [@bib24]; [@bib23]). Importantly, substitution of the middle cytosine to guanine in this motif abolishes Rap1 binding ([@bib24]; [@bib23]). To test whether Rap1 is required to bypass Pif1 activity at DNA ends, we first generated synthetic telomeric sequences with strict (TGTGG)~n~ or (TG)~n~ repeats in both 26 bp and 36 bp lengths. Unlike natural telomeres, both sequences lack a CCC motif on the opposing strand. Despite these alterations, we still observed increased telomere addition at TG~36~ ends in wild-type cells ([Figure 5b](#fig5){ref-type="fig"}; source data are available in [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}), suggesting that Rap1 binding is not required for this phenomenon.

As telomere length regulation by Rap1 is coordinated through two downstream negative regulators of telomerase, Rif1 and Rif2 ([@bib33]; [@bib68]), we asked whether these proteins are important for the DSB-telomere transition. Consistent with a Rap1-independent mechanism, telomere addition at the TG~34~ end was unaltered in *rif1Δ rif2Δ* mutants ([Figure 5c](#fig5){ref-type="fig"}; source data are available in [Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}).

Cdc13 function influences the fate of DNA ends {#s2-7}
----------------------------------------------

The Cdc13 N-terminal OB-fold domain (OB1) ([Figure 6a](#fig6){ref-type="fig"}) forms dimers ([@bib44]; [@bib60]) and in vitro can also bind telomeric ssDNA repeats of 37 and 43 bp, but not 18 and 27 bp ([@bib44]), neatly matching our observed threshold. We hypothesized that Cdc13 dimerization and its unique N-terminal binding mode might allow longer DNA ends to bypass Pif1 and sought to test this idea by disrupting dimerization with the *cdc13-L91A* mutation ([@bib44]). Consistent with this prediction, telomere addition at the TG~34~ end was inhibited by Pif1 in *cdc13-L91A* cells ([Figure 6b](#fig6){ref-type="fig"}; source data are available in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}); however, further investigation revealed a growth defect in these mutants that was suppressed by *pif1-m2* ([Figure 6c](#fig6){ref-type="fig"}). This result is reminiscent of the defective *cdc13-1* allele, which is also suppressed by loss of *PIF1* ([@bib13]; [@bib1]). High copy plasmid expression of *cdc13-L91A* was able to rescue the growth defect, but also increased telomere addition at the TG~34~ substrate ([Figure 6b](#fig6){ref-type="fig"}) arguing that the initially observed defect in *cdc13-L91A* mutants was not solely due to impaired N-terminal dimerization.

![A genetic screen to identify Cdc13 mutants that prevent telomere addition at the TG~34~ end.\
(**a**) Schematic of Cdc13 domain architecture consisting of four OB-fold domains (OB1-4) and a telomerase recruitment domain (RD). (**b**) Telomere addition frequency at the TG~18~ and TG~34~ DNA ends in *cdc13Δ* cells expressing wild-type *CDC13* (WT) or *cdc13-L91A* from a low copy (pRS415) or high copy (pRS425) plasmid. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}. (**c**) Spot assays to determine cell viability in *cdc13Δ* cells with a covering YEp-*CDC13-URA3* plasmid and pRS415- or pRS425-derived plasmids expressing wild-type Cdc13 (WT) or Cdc13-L91A. Fivefold serial dilutions of yeast cultures were grown on SD-leu as a control, and on SD-leu +5 FOA to determine viability in the absence of the covering plasmid. Plates were grown at 30°C for 2--3 days. (**d**) Schematic of a screen in TG~34~ *cdc13Δ* cells using a plate-based genetic assay for telomere addition. Repaired mutant *cdc13* plasmids were selected on SD-leu and the covering YEp-*CDC13-URA3* removed by plating on 5-FOA before DSB induction. This step also eliminates all inviable *cdc13* mutations. Plates were incubated for 2--3 days at 30°C with the exception of galactose plates which were incubated for 4 hr. An agar plate was used to reduce cell number before final selection. (**e**) Example of re-testing plate from the screen. Cdc13 mutants that prevent telomere addition are identified by the inability to grow on media containing α-aminoadipate (α-AA) (blue box), compared to positive control wild-type cells which add telomeres (red box) and TG~18~ cells that do not (white box). (**f**) Telomere addition frequency at the TG~34~ DNA end in *PIF1* and *pif1-m2* cells in a *cdc13Δ* background expressing recovered pRS425-Cdc13 mutants from the screen. Data represent the mean ± s.d. from n = 1 experiment for hits \#7--81, and n = 2 independent experiments for all *cdc13-sp* alleles. Source data are found in [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.23783.032Figure 6---source data 1.Raw data for telomere addition assays shown in [Figure 6b](#fig6){ref-type="fig"}.\
10.7554/eLife.23783.033Figure 6---source data 2.Raw data for telomere addition assays shown in [Figure 6f](#fig6){ref-type="fig"}.](elife-23783-fig6){#fig6}

We next performed a mutagenesis screen to identify *CDC13* alleles that have become sensitive to Pif1 activity ([Figure 6d,e](#fig6){ref-type="fig"}). Screening of approximately 6000 mutants led to the identification of fifteen hits that exhibited impaired telomere addition at the TG~34~ substrate. As this screen was performed in wild-type cells, we next determined if the mutations could support telomere addition in the absence of Pif1. Recovered plasmids were re-transformed into wild-type and *pif1-m2* cells, and analysis of telomere addition revealed two clones with minor phenotypes (\#7 and 14), five clones with reduced telomere addition in both wild-type and *pif1-m2* cells (\#37, 48, 79, 80, and 81), and eight clones in which telomere addition was impaired in wild-type cells but relatively unaffected in *pif1-m2* cells (\#1, 2, 3, 42, 63, 71, 72, and 77) ([Figure 6f](#fig6){ref-type="fig"}; source data are available in [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). This observation suggested that the third group of Cdc13 mutations specifically sensitize the TG~34~ end to the activity of Pif1 and are herein referred to as *cdc13-sp* alleles ([s]{.ul}ensitive to [P]{.ul}if1).

DNA sequencing revealed an average of 11 amino acid substitutions per *cdc13-sp* allele and methodical mapping experiments led to the identification of causative amino acid substitutions in six of the eight *cdc13-sp* mutants ([Table 1](#table1){ref-type="table"}, highlighted in red). Three alleles had contributions from multiple substitutions: I87N and Y758N in *cdc13-sp1*, H12R and F728I in *cdc13-sp72*, and E566V, N567D, and Q583K in *cdc13-sp3* ([Figure 7a](#fig7){ref-type="fig"}; source data are available in [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}). Cdc13-I87, like L91, is also implicated in OB1 dimerization ([@bib44]), again hinting that disrupting this function may restore Pif1 activity. The moderate telomere addition defect of Cdc13-I87N was likely only identified in the screen due to further exacerbation by the Y758N mutation ([Figure 7a](#fig7){ref-type="fig"}). The most important mutation in *cdc13-sp3* was identified to be Q583K with a minor contribution from E556V/N567D. Interestingly, all three residues are found in the canonical DNA-binding domain, suggesting that weakening the association of Cdc13 with telomeric DNA can also sensitize the TG~34~ end to Pif1.

![Cdc13 mutations that sensitize the TG~34~ end to Pif1 activity.\
(**a**) Telomere addition frequency at the TG~34~ DNA end in *PIF1* and *pif1-m2* cells in a *cdc13Δ* background expressing wild-type or mutated Cdc13 from pRS425. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}. (**b**) Telomere addition frequency at the TG~34~ DNA end in *PIF1* and *pif1-m2* cells in a *cdc13Δ* background expressing plasmid-borne wild-type or mutated Cdc13. The *cdc13-1* mutant was grown at a permissive temperature of 23°C. Data represent the mean ± s.d. from n = 3 independent experiments. Source data are found in [Figure 7---source data 2](#fig7sdata2){ref-type="supplementary-material"}. (**c**) Southern blot for telomere length of the strains examined in panel (**a**). Cells were passaged for approximately 75 generations before genomic DNA extraction. A Y' TG probe was used to label telomere sequences. (**d**) Schematic of Cdc13 domain architecture, with the most significant *cdc13-sp* amino acid mutations indicated. The majority of these mutations lie within the telomerase recruitment domain. (**e**) Telomere addition frequency at DNA ends containing 18--82 bp of TG sequence. Data represent the mean ± s.d. from a minimum of n = 3 independent experiments. Source data are found in [Figure 7---source data 3](#fig7sdata3){ref-type="supplementary-material"}.\
10.7554/eLife.23783.035Figure 7---source data 1.Raw data for telomere addition assays shown in [Figure 7a](#fig7){ref-type="fig"}.\
10.7554/eLife.23783.036Figure 7---source data 2.Raw data for telomere addition assays shown in [Figure 7b](#fig7){ref-type="fig"}.\
10.7554/eLife.23783.037Figure 7---source data 3.Raw data for telomere addition assays shown in [Figure 7e](#fig7){ref-type="fig"}.](elife-23783-fig7){#fig7}
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###### Mutations in *cdc13-sp* alleles.

pRS425-*cdc13\** plasmids were recovered from cells grown on SD-leu media that were unable to grow on α-AA containing media. *Cdc13* mutations were identified by plasmid sequencing. Mutations highlighted in red were identified by mapping experiments to determine which amino acid substitutions contribute to the mutant phenotype. Mutations highlighted in blue target important Cdc13 residues identified in this study or in previous work ([@bib47]; [@bib32]), which are predicted to contribute to the defect, although these exact substitutions were not specifically tested.

  **Allele**      **Mutations**                                                   
  --------------- --------------- ------- ------- ------- ------- ------- ------- -------
   *cdc13-sp1*    Y27F            I87N    S175P   D322G   L386M   T733A   S737C   Y758N
   *cdc13-sp3*    Q220K           L242P   E566V   N567D   Q583K   K695R           
   *cdc13-sp42*   Q36R            F58L    L131S   D150G   K161I   S170A   N194D   V217I
  S228T           S255P           K329E   L362I   F389L                           
   *cdc13-sp63*   F236S           V396I   F539Y   E716G   T756P   I767V   A807T   P896S
   *cdc13-sp72*   H12R            F96L    K129N   L179S   T291A   K296E   N426S   K469R
  E566G           E570G           I648N   F728I   P896S                           
   *cdc13-sp77*   T3P             V38A    D102G   K135N   N240Y   Q256H   E264D   T266S
  S288C           I346V           D430G   S467R   N470S   S490A   M498V   K618R   
   E636V          H687R           L721M   V725L   D792N   T779A                   
   *cdc13-sp2*    R83K            P101L   I174F   N180S   E197G   G243E   V367L   G404A
   S494P          R503G           L571R   I594M   E679G                           
   *cdc13-sp71*   H168R           I247N   E252G   T291P   V424I   K504R   F587L   T710S
  Y816H                                                                           
   clone 37       Q66R            F96L    E121K   F142L   S255L   Q256R   I342T   N378D
  E416A           L425F           L452M                                           
   clone 40       I87T            F236Y   Y626F   F665Y   T907S                   
   clone 48       F58S            T112S   F187I   F236S   E252K   A280V   D601A   S643P
   clone 79       I72V            K73R    Q94L    E192G   D219G   V238A   Q256H   K296E
  G325R           K365I           K469R   R495G   I523T   H777Q                   
   clone 80       N14K            Y70H    I72F    L436F   F575L                   
   clone 81       E121V           N180D   N199D   A231S   F236Y   M258N   M276T   G295R
  S314N           I366F           I412V   N455I   M525V   M579V   M625I   E716G   
  D773V           K909E                                                           

Three single amino acid residues (F236, S255, Q256) could completely account for the phenotype of the remaining three alleles (*cdc13-sp63*, *cdc13-sp42*, and *cdc13-sp77*, respectively; [Figure 7a](#fig7){ref-type="fig"}). These residues all map to the Cdc13 telomerase recruitment domain, suggesting that weakening the association of Cdc13 with telomerase is another means to facilitate Pif1 activity at TG~34~. In particular, the S255A mutation has previously been shown to impair telomerase recruitment, resulting in telomere shortening ([@bib20]; [@bib63]). Similarly, the classic telomerase null *cdc13-2* (E252K) mutant ([@bib47]) was also sensitive to Pif1 ([Figure 7b](#fig7){ref-type="fig"}; source data are available in [Figure 7---source data 2](#fig7sdata2){ref-type="supplementary-material"}). Telomere length in several other *cdc13-sp* alleles was also reduced in both wild-type and *pif1-m2* backgrounds, and the severity of the defect generally correlated with the magnitude of the telomere addition phenotype ([Figure 7c](#fig7){ref-type="fig"}).

The diversity of Cdc13 mutations that sensitize the TG~34~ end to Pif1 ([Figure 7d](#fig7){ref-type="fig"}) suggests that generally disrupting Cdc13 function facilitates Pif1 activity by shifting the balance away from telomere addition. In agreement with this idea, the *cdc13-1* mutant grown at permissive temperature was also sensitive to Pif1, ([Figure 7b](#fig7){ref-type="fig"}); its P371S mutation is now known to disrupt OB2 dimerization ([@bib42]). Furthermore, analysis of hits from our screen that decreased telomere addition in both wild-type and *pif1-m2* cells revealed double mutations of critical residues including S255L/Q256R in clone 37, I87T/F236Y in clone 40, and F236S/E252K in clone 48, suggesting that strongly disrupting Cdc13 function eventually impairs telomere addition even in the absence of *PIF1*. In line with this idea, the F235S/E252K/Q583K triple mutant prevented telomere addition at a TG~34~ end even in *pif1-m2* cells ([Figure 7b](#fig7){ref-type="fig"}).

The striking effect of the *cdc13* recruitment domain mutants led us to explore in greater detail how disrupting the ability of Cdc13 to recruit telomerase influences the DSB-telomere transition. We determined the telomere addition frequency of the *cdc13-Q256H* mutant on a series of DNA ends of varying telomere length ([Figure 7e](#fig7){ref-type="fig"}; source data are available in [Figure 7---source data 3](#fig7sdata3){ref-type="supplementary-material"}). While telomere addition frequency was very low at TG~34~, it gradually increased as the telomere sequence lengthened. Thus, mutating the recruitment domain of *CDC13* abolished the sharp DSB-telomere transition and increased the length of telomere sequence needed to allow telomere addition to become resistant to Pif1 action.

Discussion {#s3}
==========

The work presented here sheds light on how cells distinguish between DSBs and short telomeres and reveals a sharp transition in the fate of DNA ends with regards to their sensitivity to the telomerase inhibitor Pif1. Our findings agree with previous reports demonstrating that linear plasmid substrates containing 41 bp of telomeric repeats are efficiently converted into telomeres ([@bib38]). We find that the DSB-telomere transition also exists at natural chromosome ends and that Cdc13 is a key player in setting this transition.

The observed behavior of Pif1 complements several known mechanisms that tightly integrate telomeric sequence length and the regulation of telomerase. The identified activity of Pif1 at telomeric repeats under 34 bp joins a Mec1-dependent mechanism that inhibits Cdc13 binding at repeats under 11 bp ([@bib70]), highlighting the importance of inhibiting telomerase at DSBs. Conversely, we propose that DNA ends containing telomeric sequences of 34 bp to 125 bp are recognized as critically short telomeres and are preferentially elongated. Tel1 is implicated as a key regulator in this process ([@bib5]; [@bib55]; [@bib25]; [@bib2]; [@bib9]), although the exact phosphorylation targets are unknown ([@bib20]). Finally, the canonical counting mechanism of telomeres is known to limit the extension of long telomeres through the negative regulators Rif1 and Rif2 ([@bib41]; [@bib33]; [@bib43]; [@bib27]). Remarkably, although short telomeres of 34 bp or longer are insensitive to Pif1, Pif1 preferentially binds and acts at wild-type length or longer telomeres, thereby helping to promote the elongation of short telomeres ([@bib51]).

In order to maintain genome stability, the length of telomeric repeat sequence necessary to overcome Pif1 should be greater than any natural sequence occurring within the genome. Any longer sequences should therefore be prone to conversion into new telomeres and might be under negative selection during evolution due to the loss of genetic material. Consistent with this idea, the two longest (TG~1-3~)~n~ sequences in the correct orientation outside of telomeric regions in budding yeast include a 35 bp sequence on Chr VII, and a 31 bp sequence on Chr VI ([@bib40]).

Our investigation into the molecular trigger of the DSB-telomere transition points to a key role for the DNA-binding protein Cdc13. This conclusion is supported by work revealing that microsatellite repeats containing Cdc13-binding sites stimulate telomere addition ([@bib52]), and recent data that a hotspot on Chr V also promotes Cdc13 binding and telomere addition ([@bib48]). Furthermore, the tethering of Cdc13, but not Rap1, to this site was shown to be sufficient for the formation of new telomeres ([@bib48]). Moreover, resection at DNA ends with short stretches of telomere repeats may remove all potential Rap1-binding sites, strongly suggesting that the DSB-telomere transition depends either on ssDNA-binding proteins like Cdc13 or the ssDNA itself.

The ability of the Cdc13 OB1 domain to dimerize and bind DNA provides an attractive solution to the DSB-telomere transition; however, our results clearly indicate that sensitivity to Pif1 is not unique to any one domain and can result from a variety of mutations throughout Cdc13, most notably in the recruitment domain. Weakening the ability of Cdc13 to recruit telomerase provides a satisfying explanation for the sensitivity of the TG~34~ end to Pif1 ([Figure 8](#fig8){ref-type="fig"}) but is unable to explain why the TG~34~ end is resistant to Pif1 in the first place, especially as fusing telomerase to Cdc13 was unable to overwhelm Pif1 at the TG~18~ substrate. Interestingly, the mammalian CST complex can bind single-stranded telomeric DNA of 32 bp and longer ([@bib45]) suggesting that Cdc13 in combination with Stn1 and Ten1 may also possess unique binding properties.

![A model to explain how Cdc13 and Pif1 cooperate to establish the DSB-telomere transition.\
At the TG~18~ end, Pif1 is able to efficiently prevent telomerase-mediated extension (top left). At the TG~34~ end, Cdc13-mediated recruitment of telomerase overpowers Pif1 activity, allowing the extension of the end (top right). This is impaired if the recruitment domain of Cdc13 is mutated (bottom left). Further mutation of *PIF1* restores the ability of telomerase to elongate the TG~34~ end (bottom right).](elife-23783-fig8){#fig8}

One key unresolved issue is the mechanism by which Pif1 inhibits telomerase on either side of the DSB-telomere transition, and our results with the *pif1-4A* and *-4D* alleles suggest that these activities may be distinct. It is clear that Pif1 can remove telomerase RNA from telomeres ([@bib4]; [@bib34]), but genetic data reveal that Pif1 also has telomerase-independent activity as *PIF1* loss increases the growth of *cdc13-1 tlc1Δ* cells ([@bib10]). One potential activity for Pif1 at DSBs is through the promotion of DNA end resection, first observed in *cdc13-1* mutants ([@bib10]). Consistent with this possibility, end resection impairs telomere addition, and new telomeres are added closer to DSB sites in *pif1-m2* cells ([@bib7]). This model therefore predicts that the TG~18~ end may be resected with the help of Pif1, but that resection is blocked at the TG~34~ end, thus providing an explanation as to why tethering telomerase to the TG~18~ end does not increase telomere addition. In line with this prediction, a TG~22~ end was previously observed to partially suppress DNA end resection compared to a TG~11~ substrate ([@bib26]).

In conclusion, using Pif1 as a cellular indicator for the DNA-end fate decision reveals a striking threshold that recapitulates several properties of DSBs and telomeres. We propose that a TG~34~ DNA end, which is approximately a tenth of the size of a healthy budding yeast telomere, is interpreted by the cell as a minimal telomere.

Materials and methods {#s4}
=====================

Yeast strain construction and growth {#s4-1}
------------------------------------

The genotypes of the yeast strains used in this study are listed in [Supplementary file 1b](#supp1){ref-type="supplementary-material"}. Strains were constructed by standard allele replacement, PCR-mediated gene deletion or epitope-tagging methods, or via transformations of the indicated plasmids. The desired mutations were selected by prototrophy or drug selection and verified by PCR or sequencing. Standard yeast media and growth conditions were used ([@bib62]; [@bib58]).

Telomeric repeats were cloned into the pVII-L plasmid which features an HO endonuclease cut site, a *URA3* selection marker, and homology arms for integration at the *ADH4* locus ([@bib22]). Longer telomeric repeats were assembled using commercial gene synthesis (Mr. Gene, Regensberg, Germany) while Quikchange mutagenesis (Agilent, Santa Clara, CA) was performed for further manipulation of repeat sequences. Insertions and deletions of up to 30 bp of TG repeats were robustly obtained in a single round of mutagenesis. Quikchange-mediated shortening of a large TG~250~ sequence also yielded a wide range of shorter repeats. All repeats were verified by DNA sequencing before integration.

The TG~82~-HO cassette on Chr VII was replaced by integrating SalI and EcoRI-digested pVII-L plasmids and selecting for colonies on SD-ura. Single integration of the plasmid and HO cleavage at the locus was confirmed by Southern blot. Telomere addition strains were constructed in a *rad52Δ* background with a covering pRS414-Rad52 plasmid to facilitate genome manipulation through homologous recombination. Strains were cured of the pRS414-Rad52 plasmid by random loss in non-selective media and colonies were screened by replica-plating to SD-trp.

To make SSY76, the *GALL* promoter was amplified from plasmid pYM-N27 ([@bib29]) using primers EST1_S1 (5′-GAAAAAGTATATTCCATTAAATGACACATGCCA CCATAGATAATGCGTACGCTGCAGGTCGAC-3′) and EST1_S4 (5′-CTTGAAAAATAATCTCATACATTCTTCGTTAACTTCTTCATTATCCATCGATGAATTCTCTGTCG-3′). Correct insertion was verified by PCR with EST1.1 (5′-CAGACGAAGGTGCTTTCA-3′) and EST1.4 (5′-GCTCTTCGAGAAACCTAG-3′) primers.

Pif1 mutations were generated by Quikchange mutagenesis on a pAUR101-*pif1-m1* nuclear-specific construct and integrated at the *AUR1* locus in *pif1-m2* cells. The *est2-up34* mutation was generated by pop-in/pop-out gene replacement.

Telomere addition assays {#s4-2}
------------------------

Telomere addition assays were performed as previously described ([@bib70]). Briefly, yeast cultures were grown overnight in XY (10 g/L yeast extract, 20 g/L bactopeptone, 0.1 g/L adenine, 0.2 g/L tryptophan) + 2% glucose to log phase and subcultured into XY + raffinose (2%) for overnight growth to a density of 2.5--7.5 × 10^6^ cells/mL. Nocodazole (Sigma Aldrich, Oakville, Canada) was added at 15 µg/mL for 2 hr to synchronize cells in G2/M before addition of galactose to induce HO endonuclease expression. Cells were plated on XY +glucose plates before the addition of galactose and 4 hr after galactose addition, and grown for 2--3 days. The total number of colonies were counted, following which colonies were replica-plated to media containing α-aminoadipic acid (α-AA; Sigma-Aldrich) to identify cells that had lost the distal *LYS2* gene on Chr VII. Frequency of telomere addition was calculated as the percent of post-galactose surviving colonies that were α-AA resistant. An alternative calculation, (α-AA resistant colonies/ (pre-galactose colonies - α-AA sensitive colonies)), revealed the same threshold of Pif1 activity between the TG~18~ and TG~34~ ends, but with increased variability between experiments.

Genomic DNA extraction {#s4-3}
----------------------

Genomic DNA was isolated using a phenol-chloroform extraction protocol. Briefly, overnight cultures of cells were grown to saturation, pelleted, and resuspended with 200 µL 'Smash and Grab' lysis buffer (10 mM Tris-Cl, pH 8.0, 1 mM EDTA, 100 mM NaCl, 1% SDS, 2% Triton X-100). 200 µL of glass beads (Sigma Aldrich, 400--600 µm diameter) were added along with 200 µL phenol-chloroform (1:1). Cells were lysed by vortexing for 5 min before addition of 200 µL TE buffer (10 mM Tris-Cl pH 8, 1 mM EDTA). Samples were centrifuged at 4°C and DNA from the upper layer precipitated with the addition of 1 mL ice-cold 100% ethanol and centrifuged at 4°C. The DNA pellets were resuspended in 200 µL TE with 300 µg RNAse A (Sigma-Aldrich) and incubated at 37°C for 30 min. DNA was again precipitated with the addition of 1 mL ice-cold 100% ethanol and 10 µL of 4 M ammonium acetate, centrifuged, dried, and resuspended in TE.

Southern blots for telomere addition and length {#s4-4}
-----------------------------------------------

Fifteen micrograms of genomic DNA were digested overnight with SpeI (for TG~82~ strains) or EcoRV (for all other TG repeat lengths). Digested DNA was run on a 1% agarose gel in 0.5X TBE buffer (45 mM Tris-borate, 1 mM EDTA) at 100 V for 6 hr, denatured in the gel for 30 min with 0.5 M NaOH and 1.5 mM NaCl, and neutralized for 30 min with 1.5 M NaCl and 0.5 M Tris-Cl pH 7.5. DNA was transferred to Hybond N + membrane (GE Healthcare Life Sciences, Mississauga, Canada) using overnight capillary flow and 10X SSC buffer (1.5 M NaCl, 150 mM sodium citrate, pH 7). Membranes were UV-crosslinked (Stratalinker 1800, Agilent) and blocked at 65°C with Church hybridization buffer (250 mM NaPO~4~ pH 7.2, 1 mM EDTA, 7% SDS). Radiolabeled probes complementary to the *ADE2* (for TG~82~ strains) or *URA3 gene* (for all other TG repeat lengths) were generated from purified PCR products using the Prime-It Random labeling kit (Agilent) and α^32^-dCTP. Membranes were probed overnight, washed three times with 65°C Church hybridization buffer and exposed overnight with a phosphor screen (GE Healthcare Life Science) before imaging on a Storm or Typhoon FLA 9000 imager (GE Healthcare Life Sciences). Quantification of the added telomere signal (above CUT band) was performed in ImageQuant (GE Healthcare Life Sciences) by subtracting the background signal before HO induction followed by normalization to the internal loading control (INT). Telomere length analysis was performed by digesting genomic DNA with XhoI and probing with a Y′-TG probe generated from the pYT14 plasmid ([@bib57]) or with a telomere-specific (5′-CACCACACCCACACACCACACCCACA-3′) probe.

Inducible STEX (iSTEX) assay {#s4-5}
----------------------------

The *tlc1-tm* allele was amplified from MCY415 using primers oSMS1 (5′-ACCTGCCTTTGCAGATCCTT-3′) and TLC1-RV (5′-TTATCTTTGGTTCCTTGCCG-3′). The obtained product was transformed into SSY76 cells, which were then plated onto YPD +G418 plates. Genomic DNA of several independent transformants was prepared using a Wizard Genomic DNA Purification Kit (Promega, Leiden, Netherlands). The *TLC1* locus was again amplified using primers oSMS1 and TLC1-RV and sequenced using primer oSMS2 (5'-TGTAGATGCTTGTGTGTG-3') to confirm proper integration of the mutant *tlc1-tm* allele. Overnight cultures of *tlc1-tm* transformants were inoculated, diluted to OD~600~ = 0.1 in 25 mL YPD the next morning, and diluted again at the end of the day to OD~600~ = 0.0005 in 100 mL YPD, so that the cultures would be in log phase the morning after. Cells were then arrested with 0.045 µg/mL alpha factor (Sigma-Aldrich) for 1 hr in YPD at 30°C, spun down, resuspended in YP media containing 2% galactose and 0.0225 µg/mL alpha factor and incubated for 2 hr at 30°C. Next, cells were spun down and washed several times, resuspended in YPGal with 50 µg/mL of pronase E (Sigma-Aldrich), and cultured for 2 hr at 30°C. Cells were harvested at various points during the experiment for flow cytometry analysis and telomere PCR.

Flow cytometry {#s4-6}
--------------

Cells were fixed in 70% ethanol overnight at 4°C, washed with demineralized H~2~O (dH~2~O) and incubated in 50 mM Tris-Cl pH 8 containing 0.1 mg/mL RNase A (Thermo Fisher Scientific, Landsmeer, Netherlands, cat. no. EN0531) for 2--4 hr at 37°C. They were then spun down and resuspended in 50 mM Tris-Cl pH 7.5 containing 0.1 mg/mL proteinase K (Sigma-Aldrich, cat. no. 3115801001) and incubated for 30--60 min at 50°C. Cells were next resuspended in FACS buffer (200 mM Tris-Cl pH 7.5, 200 mM NaCl, 78 mM MgCl~2~), incubated with SYTOX Green Nucleic Acid Stain (Thermo Scientific, cat. no. S7020) in 50 mM Tris pH 7.5, and sonicated at high intensity (3 cycles of 30 s on and 30 s off) before analysis.

Telomere PCR {#s4-7}
------------

Telomere V-R and VI-R PCR was performed essentially as described ([@bib18]; [@bib5]). 1 µL of genomic DNA (\~100 ng) was mixed with 8 µL of 1x NEBuffer 4 (New England Biolabs (NEB), Ipswich, MA) and boiled for 10 min at 94°C. 1 µL of tailing mix (0.05 µL Terminal Transferase (NEB, cat. no. M0315), 0.1 µL 10x NEBuffer 4, 0.1 µL 10 mM dCTP, 0.75 µL dH~2~O) was added and incubated for 30 min at 37°C, 10 min at 65°C, and 5 min at 96°C. Immediately after tailing, 30 µl of PCR mix was added. The PCR mix consisted of 4 µL 10x PCR buffer (670 mM Tris-HCl pH 8.8, 160 mM (NH~4~)~2~SO~4~, 50% glycerol, 0.1% Tween-20), 0.32 µL 25 mM dNTP mix, 0.3 µL 100 µM telomere-specific primer (V-R: 5'-GTGAGCGGATAACAATTTCACACAGTCTAGATGTCCGAATTGATCCCAGAGTAG-3' or VI-R: 5'-ACGTGTGCGTACGCCATATCAATATGC-3'), 0.3 µL 100 µM G~18~ primer (5'-CGGGATCCG~18~-3'), 0.5 µL Q5 High-Fidelity DNA Polymerase (NEB, cat. no. M0491), 24.68 µL dH~2~O. The samples were denatured at 98°C for 3 min, followed by 35 cycles of 98°C for 30 s and 68°C for 15 s, and a final extension step at 72°C for 2 min.

Gel extraction, cloning, and sequencing {#s4-8}
---------------------------------------

Telomere PCR products were separated on 2.5% agarose gels and extracted using a NucleoSpin^®^ Gel and PCR Clean-up kit (Macherey-Nagel, Düren, Germany, cat. no. 740609). The purified PCR products were then cloned using a Zero Blunt TOPO PCR Cloning Kit (Thermo Fisher Scientific, cat. no. 450245). Individual clones were sequenced by GATC Biotech (Cologne, Germany) and the resulting data were analyzed using Sequencher software (Gene Codes, Ann Arbor, MI).

PCR mutagenesis screens {#s4-9}
-----------------------

Mutant alleles were generated by error-prone PCR using Taq polymerase (New England Biolabs) and 0.25 mM MnCl, and purified using spin columns (Qiagen, Mississauga, Canada). The Pif1 mutagenesis screen was performed in TG~82~*pif1-m2* cells co-transformed with gapped pRS416-*pif1-m1* and purified inserts. Cells harbouring repaired plasmids were selected on SD-ura. The Cdc13 mutagenesis screen was performed in TG~34~*cdc13Δ* cells containing a covering YEp-*CDC13-URA3* plasmid and co-transformed with gapped pRS425-*CDC13* plasmid and PCR inserts. Cells harboring repaired plasmids were selected on SD-ura before replica-plating to 5-fluoroorotic acid (5-FOA) to remove the covering plasmid. Mutant *cdc13* alleles that are defective in capping should be inviable at this step. Colonies from both screens were patched onto raffinose plates and grown for 2 days before replica plating to galactose plates for 4 hr, and finally to α-AA plates after reducing cell density by first replicating plating to a blank agar plate. Plasmids were rescued using a phenol-chloroform extraction and transformed into *Escherichia coli*. Plasmids were sequenced to identify mutations and retransformed into the parental yeast strain to confirm that the phenotype resulted from the plasmid mutation.

Statistics {#s4-10}
----------

The statistics carried out in [Figure 2](#fig2){ref-type="fig"} were done using a Fisher's exact test and for this analysis, telomeres containing only wild-type divergence were excluded.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A sharp Pif1-dependent threshold separates DNA double-strand breaks from critically short telomeres\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Reviewing Editor Kathleen Collins and Kevin Struhl as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Teresa Teixeira (Reviewer \#3); Dorothy Shippen (Reviewer \#4).

The Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Cells must distinguish short telomeres from DNA double strand breaks to preserve genome stability, yet the mechanism that underlies the distinction remains poorly understood. Recent studies implicate the Pif1 helicase as a pivotal player in determining the fate of these two types of chromosome termini. Here the authors investigate the mechanism by which Pif1 from *S. cerevisiae* blocks de novo telomere formation on DSBs with less than 26bp of telomeric DNA, but not at tracts of longer telomere sequence. Using a classical HO-induced DSB system, and a single molecule telomere length assay, the authors establish a telomere length \"window\" of \~26-40bp that distinguishes DSBs from short telomeres.

To examine how Pif1 activity is repressed at telomeric DNA sequences that exceed this length threshold, they use a genetic approach to test the contributions of DDR kinases (Mec1, Tel1 and Rad53), telomerase recruitment, and Pif1 phosphorylation. They find no correlation with Pif1 activity at telomeres longer than the \"DSB-telomere transition length\". Similarly, Rap1 binding does not significantly impact Pif1 activity. However, the authors find a correlation between various aspects of Cdc13 function and Pif1 activity at telomeres longer than 34bp. Using a suppressor screen they identify numerous residues in Cdc13 important for suppressing Pif1 activity.

This study is important for its discovery of a link between Cdc13 and Pif1 in distinguishing DSBs from short telomeres. Overall the study was solid technically and communicated clearly, with a few omissions detailed below. The major shortcoming of the work is that it doesn\'t satisfyingly resolve the nature of the link between Cdc13 and Pif1 in the context of previously known properties/roles of Cdc13. The impact of the study could be considerably strengthened by additional mechanistic insight about how Cdc13 modulates Pif1 activity at different DNA ends.

Essential revisions:

1\) Major experiments using the HO cut assay are elegant and well controlled. However, the evidence that what is learned applies to native telomeres is less strong because it lacks the positive control in *pif1-m2* background. This control would be ideal to show that absence of telomerase action at critically short telomeres is not due to some transient cell cycle arrest due checkpoint activation or cell death in the (small) portion of cells containing the exact same critically short telomeres we are looking at. Note that despite differences in the experimental settings, STEX is done 2h after telomerase re-expression, while in Southerns shown for the HO cut we see no telomere elongation at this time point after Gal addition to induce HO. This is challenging (need to construct an inducible system for Pif1 to prevent telomeres from lengthening before the experiment), but it would help in more confidently extend the conclusions to native ends. Alternatively, STEX could be tried in mutants of MEC1 or RAD53, but it\'s not obvious that these mutations wouldn\'t affect telomerase action at these very short telomeres (see effect at TG82-HO in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Anyway, authors should try to provide evidence that the portion of cells carrying the critically short telomeres contain active telomerase.

2\) The STEX result in [Figure 2](#fig2){ref-type="fig"} (reduced telomere addition to very short endogenous telomeres) is at odds with a number of published STEX results that don\'t show this effect. How do the authors explain this discrepancy? How do the authors eliminate the possibility that use of a mutant template sequence alters the results? I do not understand the derivation of the p value given for the VI-R telomeres. The Fisher Exact Test gives a p value of 0.07 (75 extended and 159 not extended among the longer telomeres vs. 0 extended and 7 not among the shortest telomeres). How do the authors justify using a different cut-off length in the two cases?

3\) The authors state in the Materials and methods that the total cell counts both pre- and post-galactose treatment are obtained, but the fraction of cells that survive the 4-hour treatment with galactose is not given. Could the authors comment whether this rate differs greatly between situations in which the end either is or is not efficiently healed by telomere addition?

4\) In several experiments, the authors fail to see an effect on TG34-HO healing by expression of a *pif1-m1* allele in a *pif1-m2* strain ([Figure 3D](#fig3){ref-type="fig"} for the 5AQ allele and [Figure 4C](#fig4){ref-type="fig"} for the 4D allele). The authors should verify that the mutant Pif1 protein is expressed and functional by virtue of its ability to complement the telomere lengthening phenotype of the *pif1-m2* allele.

5\) If \"WT\" results are presented in multiple figures, the legend must clearly state that data are identical to those shown previously. See [Figures 3C](#fig3){ref-type="fig"}, [4E](#fig4){ref-type="fig"}, [5A](#fig5){ref-type="fig"}, and 5C. Are the same *sml1* and *sml1 pif1-m2* data shown in panels B and D of [Figure 3--- -- figure supplement 1](#fig3s1){ref-type="fig"}? What is the n value for these samples?

6\) In [Figure 6B](#fig6){ref-type="fig"}, the authors should show the effect of high copy expression in the TG18 PIF1 and *pif1-m2* strains. Low copy Cdc13 does not fully complement since telomere addition at TG18 in the *pif1-m2* background is less than half of what is seen in other experiments. Does overexpression of WT Cdc13 render TG18 partially or fully resistant to Pif1 action?

7\) In [Figure 8A](#fig8){ref-type="fig"}, the effect of the cdc13-S255A mutation is particularly strong, but this mutant is not included on the telomere length analysis of [Figure 8B](#fig8){ref-type="fig"}. Why? If a mutation like S255A raises the threshold (in terms of telomere length) required for an end to become resistant to Pif1 action, one might predict that longer telomeric seeds will regain that ability. It would be informative to repeat the experiment in [Figure 1C](#fig1){ref-type="fig"} with one of the stronger cdc13 alleles (or at least to check one of the longer TG strains) to test this idea.

8\) In the Discussion, the authors provide only a cursory mention of nucleolytic resectioning at the HO cut site prior to telomere addition. The DNA substrate that arises following HO cleavage will be grossly distinct from a natural short telomere, but this is glossed over in the text. Because resectioning is not discussed, the rationale for looking at the contribution of the double strand telomere binding protein RAP1 versus the single strand telomere protein Cdc13 is not established. Clearly, the 3\' overhang depicted in [Figure 1B](#fig1){ref-type="fig"} is not consistent with the major conclusions from the paper. A more accurate description of the actual substrate for action at the \"DSB-telomere transition\" is required.

9\) In the last paragraph of the subsection "Identification of a Pif1-insensitivity threshold at DNA ends", a major conclusion of this paper is there is a sharp boundary for the DSB-telomere transition length between 26 to 34bp. [Figure 1E](#fig1){ref-type="fig"} provides evidence to support this conclusion. However, with the TG30 sequence there is a 30% addition rate, arguing that the addition frequency actually gradually increases inside this window. Additional experiments that test Pif1 activity on TG28 and TG32 are needed to determine whether there is indeed a sharp length threshold or a more diffuse window. Furthermore, according to the hypothesis that Pif1 regulation is mediated by Cdc13 binding to DNA and that three Cdc13 binding sites are needed for regulation (11bp each), then both TG30 and TG26 should be insensitive to Pif1 activity since neither contain three complete Cdc13 binding sites.

10\) The suppressor screen is powerful, but the data provide little molecular insight into how Cdc13 impedes Pif1 function. Mutations localize in the vicinity of different functional domains of Cdc13. To emphasize this point, the authors should provide a diagram (not a table) of residues identified in the suppressor screen to show their position within Cdc13 relative to known functional elements (dimerization, telomerase recruitment, DNA binding). The authors begin to dissect the contribution of such functional domains (e.g. dimerization) by assessing the cdc13-L91A mutation in their telomere addition assay. In addition, they should directly evaluate that contribution Cdc13 DNA binding and telomerase recruitment on Pif1 regulation using other biochemically validated mutants. This is essential because the authors have not provided any evidence that the residues they identified in their genetic screen are in fact important for specific Cdc13 functions. Consequently, we are left with no clear hypothesis for how Cdc13 regulates Pif1.

10.7554/eLife.23783.043

Author response

*Essential revisions:*

*1) Major experiments using the HO cut assay are elegant and well controlled. However, the evidence that what is learned applies to native telomeres is less strong because it lacks the positive control in pif1-m2 background. This control would be ideal to show that absence of telomerase action at critically short telomeres is not due to some transient cell cycle arrest due checkpoint activation or cell death in the (small) portion of cells containing the exact same critically short telomeres we are looking at. Note that despite differences in the experimental settings, STEX is done 2h after telomerase re-expression, while in Southerns shown for the HO cut we see no telomere elongation at this time point after Gal addition to induce HO. This is challenging (need to construct an inducible system for Pif1 to prevent telomeres from lengthening before the experiment), but it would help in more confidently extend the conclusions to native ends. Alternatively, STEX could be tried in mutants of MEC1 or RAD53, but it\'s not obvious that these mutations wouldn\'t affect telomerase action at these very short telomeres (see effect at TG82-HO in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Anyway, authors should try to provide evidence that the portion of cells carrying the critically short telomeres contain active telomerase.*

The reviewers raise an important point. We have completed the *pif1-m2* iSTEX controls (see revised [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). At telomere VR, there is a statistically significant increase in the extension of telomeres below the DSB-telomere boundary in *pif1-m2* cells. A similar result is seen for telomere VI-R, but the number of short telomeres was not sufficient to reach statistical significance (p=0.151) despite our best efforts to accrue the number of short telomeres. Nevertheless, our new findings strengthen our conclusion that there is a telomereDSB transition at native telomeres that is regulated by Pif1.

*2) The STEX result in [Figure 2](#fig2){ref-type="fig"} (reduced telomere addition to very short endogenous telomeres) is at odds with a number of published STEX results that don\'t show this effect. How do the authors explain this discrepancy? How do the authors eliminate the possibility that use of a mutant template sequence alters the results? I do not understand the derivation of the p value given for the VI-R telomeres. The Fisher Exact Test gives a p value of 0.07 (75 extended and 159 not extended among the longer telomeres vs. 0 extended and 7 not among the shortest telomeres). How do the authors justify using a different cut-off length in the two cases?*

This comment can be subdivided in a number of points. First, regarding the comparison of our results with those of the literature, we note that there are only four papers that show STEX data (Teixeira et al., 2004; Arnerić and Lingner, 2007; Ji et al., 2004; Phillips et al., 2015). The Philips et al. paper is not highly relevant to this comment because there was a high background of telomerase-independent divergence events at telomeres below 50 nt in length. The other papers did indeed show some extension events at telomeres below our 30-40 nt threshold, but their sample size was quite small in each of these studies. However, it is critical to note that since those studies used strains with wild-type telomerase, it is simply impossible to differentiate between telomerase-dependent and -independent events, and therefore it is impossible to assess how many of the divergence events observed in the previous papers were due to telomerase activity.

As for the second point regarding the impact of the telomerase template, we contend that it is unlikely that the mutant template alters the iSTEX results for the following reasons. First, the incipient telomeres are wild-type and we only express the mutant telomerase for a single cycle. Second, previous work (Chang et al., 2007) alongside the present work here show no difference in terms of repeat addition processivity, frequency of extension, length of extension, and preferential elongation of short telomeres by the mutant template-containing telomerase. This important point is now emphasized in the first paragraph of the subsection "A DSB-telomere transition also exists at chromosome ends".

With respect to the third point, the reviewers were correct and we had indeed miscalculated the p value in the original [Figure 2](#fig2){ref-type="fig"}. During the revision period, the number of sequenced telomeres accrued and a new p value is now reported (p=0.039).

As for the last point, the difference in the DSB-telomere threshold for telomere V-R (43 nt) and telomere VI-R (37 nt) is likely due to experimental variation and/or the sample size of telomere ends analyzed by iSTEX. We contend that the 6-nt difference is a rather small difference. In addition, the exact sequences of these telomeres are different, and this may impact somewhat the threshold length.

*3) The authors state in the Materials and methods that the total cell counts both pre- and post-galactose treatment are obtained, but the fraction of cells that survive the 4-hour treatment with galactose is not given. Could the authors comment whether this rate differs greatly between situations in which the end either is or is not efficiently healed by telomere addition?*

The fraction of cells that survive the 4-h treatment with galactose varies from 10% to 40%, and this variation cannot be easily explained by genotype or TG length. We believe this variation could be due to differences in HO-cutting efficiency from experiment to experiment. This difference does not alter in any way the interpretation of our results. Whether we calculate telomere addition frequency from the total number of cells or from only the surviving cells, TG18 is sensitive to PIF1 status while TG34 is not ([Author response image 1](#respfig1){ref-type="fig"}).

![Telomere addition frequency at DNA ends containing 18 or 34 bp of TG sequence normalized either to the total amount of cells (total) or only the surviving cells after the 4h galactose induction (surviving).\
Data represent the mean ± s.d. from a minimum of n=3 independent experiments.](elife-23783-resp-fig1){#respfig1}

*4) In several experiments, the authors fail to see an effect on TG34-HO healing by expression of a pif1-m1 allele in a pif1-m2 strain ([Figure 3D](#fig3){ref-type="fig"} for the 5AQ allele and [Figure 4C](#fig4){ref-type="fig"} for the 4D allele). The authors should verify that the mutant Pif1 protein is expressed and functional by virtue of its ability to complement the telomere lengthening phenotype of the pif1-m2 allele.*

This is a good point. We have now included a new experiment (revised [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}) that shows, as expected, that the *pif1-m1* allele rescues the telomere lengthening phenotype of the *pif1-m2* allele.

*5) If \"WT\" results are presented in multiple figures, the legend must clearly state that data are identical to those shown previously. See [Figures 3C](#fig3){ref-type="fig"}, [4E](#fig4){ref-type="fig"}, [5A](#fig5){ref-type="fig"}, and 5C. Are the same sml1 and sml1 pif1-m2 data shown in panels B and D of [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}? What is the n value for these samples?*

We apologize for the oversight. The mentioned figures (3C, 4E, 5A, 5C) did indeed show the same WT data. The telomere addition of *sml1∆* cells is also the same in panels B and D of [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} (n=3). The figure legends have been modified to explicitly mention this.

*6) In [Figure 6B](#fig6){ref-type="fig"}, the authors should show the effect of high copy expression in the TG18 PIF1 and pif1-m2 strains. Low copy Cdc13 does not fully complement since telomere addition at TG18 in the pif1-m2 background is less than half of what is seen in other experiments. Does overexpression of WT Cdc13 render TG18 partially or fully resistant to Pif1 action?*

This is a good suggestion. As requested, we have tested the impact of high-copy expression of *CDC13* and *cdc13-L91A* in the *PIF1* and *pif1-m2* strains (revised [Figure 6b](#fig6){ref-type="fig"}). Overexpression of wild-type *CDC13* clearly does not render TG~18~ resistant to Pif1 action and therefore the differences seen between low- and highcopy expression was specific for *cdc13-L91A*.

*7) In [Figure 8A](#fig8){ref-type="fig"}, the effect of the cdc13-S255A mutation is particularly strong, but this mutant is not included on the telomere length analysis of [Figure 8B](#fig8){ref-type="fig"}. Why? If a mutation like S255A raises the threshold (in terms of telomere length) required for an end to become resistant to Pif1 action, one might predict that longer telomeric seeds will regain that ability. It would be informative to repeat the experiment in [Figure 1C](#fig1){ref-type="fig"} with one of the stronger cdc13 alleles (or at least to check one of the longer TG strains) to test this idea.*

The *cdc13-S255A* mutation has previously been shown to have short telomeres by two independent groups (Tseng et al., 2006; Gao et al., 2010). This has now been noted in the fourth paragraph of the subsection "Cdc13 function influences the fate of DNA ends" and the work are cited. To answer the second part of the reviewers' comments, we have tested the *cdc13-Q256H* mutant across a range of TG substrates (see new [Figure 8E](#fig8){ref-type="fig"}). As predicted, we find that the *cdc13-Q256H* mutant has the ability to elongate longer TG substrates. Interestingly, the threshold is no longer as sharp as in the wild-type situation, but instead is more gradual.

*8) In the Discussion, the authors provide only a cursory mention of nucleolytic resectioning at the HO cut site prior to telomere addition. The DNA substrate that arises following HO cleavage will be grossly distinct from a natural short telomere, but this is glossed over in the text. Because resectioning is not discussed, the rationale for looking at the contribution of the double strand telomere binding protein RAP1 versus the single strand telomere protein Cdc13 is not established. Clearly, the 3\' overhang depicted in [Figure 1B](#fig1){ref-type="fig"} is not consistent with the major conclusions from the paper. A more accurate description of the actual substrate for action at the \"DSB-telomere transition\" is required.*

The reviewers raise an interesting point and we agree that the resection of DNA ends would preclude Rap1 from binding in the first place. We should have mentioned the impact of resection on short telomeric substrates in the original Discussion. Furthermore, since the G-tails of very short telomeres also likely remove Rap1 binding sites, ssDNA formation at DSBs and critically short telomeres further suggests that Cdc13 rather than Rap1 regulates the DSB-telomere transition. We now mention this possibility in the revised Discussion.

The reviewers should also note that the DNA substrate depicted in [Figure 1B](#fig1){ref-type="fig"} is the structure produced immediately after HO cleavage. This was noted in the figure legend and it was never intended to suggest that this was the substrate at the time of telomerase action. Since extensive resection inhibits de novo telomere addition, one could predict that the exact structure of the cleaved TG~34+~-HO substrates would be similar, to some extent, to that of a short telomere with a G-tail.

*9) In the last paragraph of the subsection "Identification of a Pif1-insensitivity threshold at DNA ends", a major conclusion of this paper is there is a sharp boundary for the DSB-telomere transition length between 26 to 34bp. [Figure 1E](#fig1){ref-type="fig"} provides evidence to support this conclusion. However, with the TG30 sequence there is a 30% addition rate, arguing that the addition frequency actually gradually increases inside this window. Additional experiments that test Pif1 activity on TG28 and TG32 are needed to determine whether there is indeed a sharp length threshold or a more diffuse window. Furthermore, according to the hypothesis that Pif1 regulation is mediated by Cdc13 binding to DNA and that three Cdc13 binding sites are needed for regulation (11bp each), then both TG30 and TG26 should be insensitive to Pif1 activity since neither contain three complete Cdc13 binding sites.*

Although the word "sharp" is obviously subjective, when viewed in the context of a full-length telomere (\~300 bp), we believe the transition window (\~8 bp) from a Pif1sensitive to a Pif1-insensitive end is quite narrow. To further highlight this point, when the DSB-transition is altered by mutation of *CDC13*, the transition is much more gradual (see revised [Figure 8E](#fig8){ref-type="fig"}). In addition, the TG~30~ telomere addition rate (as shown in [Figure 1E](#fig1){ref-type="fig"}) is 19% (normalized to *pif1-m2*), not 30%.

While it is true that the minimum length for Cdc13 binding was determined to be 11 bp, there is no evidence to suggest that three Cdc13 molecules would bind a 33 bp telomere sequence. Indeed, steric hindrance could well prevent this from occurring. To avoid confusion, these sentences have now been removed from the text.

*10) The suppressor screen is powerful, but the data provide little molecular insight into how Cdc13 impedes Pif1 function. Mutations localize in the vicinity of different functional domains of Cdc13. To emphasize this point, the authors should provide a diagram (not a table) of residues identified in the suppressor screen to show their position within Cdc13 relative to known functional elements (dimerization, telomerase recruitment, DNA binding). The authors begin to dissect the contribution of such functional domains (e.g. dimerization) by assessing the cdc13-L91A mutation in their telomere addition assay. In addition, they should directly evaluate that contribution Cdc13 DNA binding and telomerase recruitment on Pif1 regulation using other biochemically validated mutants. This is essential because the authors have not provided any evidence that the residues they identified in their genetic screen are in fact important for specific Cdc13 functions. Consequently, we are left with no clear hypothesis for how Cdc13 regulates Pif1.*

As requested, we now included in the revised manuscript a diagram of Cdc13 with the strongest mutations indicated (revised [Figure 8D](#fig8){ref-type="fig"}). The S255A mutant has previously been carefully studied and shown to be defective in telomerase recruitment (Gao et al., 2010). We have now included telomere addition assays for the *cdc13-2* (E252K) mutant, which is also known to be defective in telomerase recruitment (revised [Figure 8B](#fig8){ref-type="fig"}).

[^1]: These authors contributed equally to this work.
